Kornimate/medical-research-clean huggingface dataset:
research study of treatment for winter depression with different colors of light

Conditions: Seasonal Affective Disorder

Summary: the specific aim of this study is to test the hypothesis that light stimuli concentrated around 467 nm will evoke a significantly stronger therapeutic response in sad patients compared to light stimuli concentrated around 657 nm at an equal photon density. the secondary objective of this study is to determine the efficacy of different colors and levels of light in order to optimize therapeutic benefit, while also minimizing side effects and maintaining safety of light exposure.

studies report as many as 1 out of every 5 americans is affected by mild to severe seasonal affective disorder (sad, winter depression). although the exact cause of this condition is unknown, bright light has proven to be an effective therapeutic treatment for many people with sad. the light sources that have been traditionally used for treatment of sad produce white light with great variability in the balance of wavelengths that are emitted across the visible spectrum. although several studies have attempted to test the effectiveness of different wavelengths for treatment of sad, the devices used in those studies employed broad bandwidths of light. with the technological advancements in light emitting diodes (leds) the production of new light therapy equipment with much narrower bandwidths of light is possible. side effects of exposure to traditional white light therapy for sad have included hypomanic activation, irritability, headache, eyestrain and nausea. we hypothesize that when the wavelength of light therapy is optimized, it should be feasible to elicit strong therapeutic benefits with lower light intensities and fewer side effects. previous studies, approved by the jefferson irb and successfully completed by our laboratory have shown that some colors of light are more effective in treating sad than other colors.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of seasonal affective disorder * over 18 years old * stable sleeping pattern with a bedtime no later than 1 a.m. exclusion criteria: * pregnant women * concurrent psychiatric illness that would preclude compliance with the protocol * active suicidal or homicidal ideation or plan * variable psychiatric illness (i.e. rapid cycling disorder or severe premenstrual syndrome) * individuals with substance abuse or dependence who have not been in remission for at least one year * individuals taking photosensitizing medications * individuals with macular degeneration or other ocular conditions which might be adversely affected by light * less then six weeks after onset of psychotherapeutic treatment

Keywords: seasonal affective disorder
to evaluate ssd8432/ritonavir in adults with covid-19

Conditions: COVID-19

Summary: this is a randomized, double-blind, placebo-controlled, phase ii/iii clinical study to evaluate the efficacy and safety of ssd8432 in combination with ritonavir in adult subjects with mild/common covid-19.

this is a randomized, double-blind, placebo-controlled, phase ii/iii clinical study to evaluate the efficacy and safety of ssd8432 in combination with ritonavir in adult subjects with mild/common covid-19. this study plan to enroll 670 mild or common type adult covid-19 subjects, randomly assigned to the experimental group and the control group according to 1:1, experimental group:335subjects will receive ssd8432 and ritonavir; control group :335subjects will receive ssd8432 placebo and ritonavir placebo.

Eligibility criteria:
inclusion criteria: 1. ≥18 and ≤80 years old, male or female. 2. initial positive test of sars-cov-2 within 5 days of randomization. 3. mild or common type of covid-19. 4. initial onset of covid-19 signs/symptoms within 3 days of randomization. 5. fever or 1 respiratory symptom of covid-19 on random day 6. subjects without high risk factors 7. subjects with at least one high-risk factor exclusion criteria: 1. transnasal high-flow oxygen therapy or non-invasive ventilation, invasive mechanical ventilation, or ecmo is required or anticipated to be urgently required. 2. prior to current disease episode, any confirmed sars-cov-2 infection. 3. known medical history of active liver disease (other than nonalcoholic hepatic steatosis). 4. receiving dialysis or have known moderate to severe renal impairment. 5. known human immunodeficiency virus (hiv) infection. 6. suspected or confirmed concurrent active systemic infection other than covid-19 that may interfere with the evaluation of response to the study intervention. 7. oxygen saturation of ≤ 93% on room air obtained at rest within 24 hours prior to randomization.. 8. treatment with antivirals against sars-cov-2 within 14 days. 9. current or expected use of any medications or substances that are highly dependent on cyp3a4 for clearance. 10. concomitant use of any medications or substances that are strong inducers of cyp3a4 are prohibited within 28 days. 11. has received or is expected to receive covid-19 monoclonal antibody, convalescent covid-19 plasma or other prohibited concomitant medication. 12. females who are pregnant or breastfeeding.
neuromodulation with rtms in dysphagic patients with stroke

Conditions: Transcranial Magnetic Stimulation

Summary: the patients with chronic dysphagia secondary to first-ever stroke were randomly assigned to 2 groups: group a: sham stimulation for 10 minutes , group b: real rtms for 10 minutes. rtms conditioning: daily rtms 10 min for 10 days. assessments: 1. videofluoroscopy，2.functional outcome swallowing scale (3 scales). 3. mep measurements

while the reﬂex component of swallowing depends on swallowing centres in the brainstem, initiation of swallowing is a voluntary action that involves the integrity of motor areas of the cerebral cortex. oropharyngeal dysphagia occurs in more than 50% of stroke patients. aspiration pneumonia occurs in up to 20% of acute stroke patients and is a major cause of mortality after discharge. oropharyngeal dysphagia is both underestimated and underdiagnosed as a cause of major nutritional and respiratory complications in stroke patients. recently, transcranial magnetic stimulation (tms) has been used to study the cortical input to swallowing control and has revealed that the topographic representation of esophageal motor function in the human cerebral cortex is bilateral but with consistent interhemispheric asymmetry unrelated to handedness. in a number of recent studies, poststroke motor and dysphagia performance has been improved after daily treatment sessions with repetitive tms (rtms) using an excitatory frequency in patients with hemispheric ischaemic stroke due to occlusion of territories of the middle cerebral artery. our hypothesis was that rtms would facilitate dysphagia recovery.

Eligibility criteria:
inclusion criteria: 1. a diagnosis of stroke related dysphagia 2. no concurrent neurodegenerative or dementia history 3. an absence of tms contraindications. exclusion criteria: * arrythmia, epilepsy, infection, hyperglycemia, pacemaker or implants, external ventricular drain or ventriculoperitoneal shunt

Keywords: dysphagia repetitive transcranial magnetic stimulation stroke
jinghua weikang capsule containing quadruple therapy for igan with helicobacter pylori infection

Conditions: Helicobacter Pylori Infection

Summary: this study is to evaluate the efficacy and safety of the jinghua weikang capsule (a chinese patent medicine for peptic ulcer and gastritis) containing quadruple therapy (jinghua weikang caplsule plus triple therpy) for eradicating helicobacter pylori in iga nephropathy.


Eligibility criteria:
inclusion criteria: * iga nephropathy diagnosed by renal biopsy; * current helicobacter pylori infection; * age 18-65. exclusion criteria: * ①egfr\<90ml/（min·1.73m2）- * history of helicobacter pylori treatment * present taking hormones or immunosuppressants * malignant tumor and high-grade intraepithelial neoplasia and severe dysplasia of gastric mucosa * allergy history to medicines used in the study * history of gastric surgery * uncontrolled chronic diseases such as diabetes, cardiovascular and cerebrovascular diseases, respiratory diseases, mental disorders and other researchers are considered to affect treatment and assessment * combined with other primary or secondary nephropathy except for igan * combined with acute renal injury * female patients with pregnancy, lactation and planned pregnancy.

Keywords: helicobacter pylori iga nephropathy jinghua weikang caplsule bismuth-containing quadruple therapy eradication
postoperative cognitive function and eeg

Conditions: Aging; Postoperative Cognitive Dysfunction; EEG With Periodic Abnormalities

Summary: in the elderly patients undergoing elective non-cardiac major surgery, the differences of eeg parameters between those with and without postoperative cognitive dysfunction were observed to determine the characteristic changes of eeg parameters related to postoperative cognitive dysfunction


Eligibility criteria:
inclusion criteria: 1. aged 65 and above 2. non-cardiac surgery under general anesthesia; 3. american society of anesthesiology(asa) classification i- ii 4. patients aged 18-40 years old are set as background exclusion criteria: 1. patients with central nervous system diseases and mental diseases 2. preoperative minimal mental status examination(mmse) score\<24; 3. asa status iii or higher 3) those who have received less than 5 years of education since entering primary school; 4) history of sedatives or antidepressants use; 5) existed or anticipated alcohol or drug abuse(over 40°c and over 100ml per day for the past 3 months); 6) history of surgery within the previous year; 7) those with severe visual or hearing impairment; 8) those participated in other clinical studies within last 3 months;

Keywords: noncardiac surgery elderly patients postoperative cognitive dysfunction electroencephalogram
12-week safety evaluation of oral cs-0777 in multiple sclerosis patients

Conditions: Multiple Sclerosis

Summary: this is a 12-week study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of oral cs-0777 in patients with multiple sclerosis.


Eligibility criteria:
inclusion criteria: * diagnosis of clinically isolated syndrome or a relapsing form(s) of ms, based on poser or mcdonald criteria (may include patients with secondary progressive disease) * clinical relapse within the past 3 years or a gadolinium enhancing lesion on a brain mri scan within the past 12 months * baseline edss score of 0 - 6.5 * female subjects who are sexually active, unless sterile or post-menopausal for at least 1 year, must be willing to use double-barrier contraception exclusion criteria: * primary progressive ms * any medical condition that predisposes to immunocompromise * history of malignancy, tuberculosis, invasive fungal infections, herpes zoster infection (or shingles), or other opportunistic infection, or any current active infection * concurrent diagnosis of any other autoimmune disease (eg, rheumatoid arthritis or lupus) * treatment with cyclophosphamide or mitoxantrone within 6 months of study initiation * treatment with cyclosporine, azathioprine, methotrexate or other immunosuppressant within 3 months of study initiation * treatment with interferon beta or glatiramer acetate within 2 months of study initiation * prior treatment with natalizumab or rituximab

Keywords: multiple sclerosis, relapsing, secondary progressive, clinically isolated syndrome, mri
determining the impact of a physiotherapist-led primary care model for hip and knee pain - a pilot trial

Conditions: Hip Osteoarthritis; Knee Osteoarthritis

Summary: this is a pilot cluster randomized controlled trial to to evaluate the individual and health system impacts of implementing a new physiotherapist-led primary care model for hip and knee pain in canada.

arthritis is one of the leading causes of pain, disability, and reduced quality of life in patients. arthritis currently affects one in five canadians (six million), which is expected to rise to nine million people by 2040. osteoarthritis (oa) is the most common forms of arthritis, with hip and knee being two of the most common locations. for most people, the first point of contact for their pain is their primary care provider. due to the rise in patients seeking support at the primary care level, the shortage of primary care providers, and the high burden on these providers, patients often do not receive timely access to the care they require. a promising strategy is to have an integrated model of care where a physiotherapist (pt) is the first point of contact within interprofessional primary care teams. pts can provide a comprehensive and efficient management strategy for patients presenting to their primary care provider with hip and knee pain complaints. this study aims to determine the feasibility of conducting a cluster randomized trial in primary care settings in ontario to evaluate the individual health outcomes and health system impact of implementing a new physiotherapist-led primary care model for people with hip and knee pain. the primary objectives of this pilot study are: 1. determine the feasibility of participant recruitment, assessment procedures, and retention. 2. determine the feasibility of implementing a new pt led primary care model for hip and knee pain. 3. explore the perspectives of patient participants and hcps related to their experiences and attitudes towards the new service delivery model, barriers/facilitators to implementation, perceived satisfaction, perceived value and impact on clinic processes and patient participant outcomes.

Eligibility criteria:
inclusion criteria: - adults \>= 19 years who ask to book a primary care visits where the primary reason is for hip or knee pain of any duration. exclusion criteria: * cannot understand, read, and write english * known cancer causing hip or knee pain
sonazoid in myocardial perfusion imaging

Conditions: Diagnostic Imaging; Myocardial Ischemia

Summary: currently, sonazoid is mainly used for imaging liver lesions by assessing perfusion characteristics. however, the ultrasound technology is the same as for cardiac imaging and the stability of the microbubbles will potentially aid the detection of myocardial perfusion defects. this study will look at the feasibility of using sonozoid in this way.

ultrasound contrast agents are gas-filled microbubbles that enhance the visualisation of cardiac structures, function and blood flow. myocardial contrast echocardiography enables us to visualise myocardial perfusion and provides incremental information for diagnosis of coronary artery disease (cad) and prognosis beyond wall motion assessment . using ultrasound at low acoustic power (low/intermediate mi) causes the microbubbles to oscillate resulting in giving off non-linear signals which are different from tissues which gives off linear signals. the first contrast agents were used in 1968. since then the technology has been refined and now the microbubbles are more stable and consist of an inert gas encapsulated in a lipid or albumin shell. these microbubbles remain intact in the systemic circulation because of their small size can transit through the pulmonary circulation. the indication for myocardial perfusion imaging is when vasodilator stress like dipyridamole is performed. vasodilators do not readily induce wall motion abnormalities but cause perfusion defects to occur which allows detection of cad. myocardial perfusion imaging is also indicated during treadmill or dobutamine stress when suspicion of cad is high as it is more sensitive than wall motion for the detection of cad. myocardial perfusion imaging looks at a uniformity of contrast appearance in the myocardium, following a continuous microbubble infusion. if there is decreased perfusion, the appearance of contrast will be delayed and the opacification will not be uniform. the advantage of sonazoid over the other frequently used contrast agents (sonovue, luminity, optison) is that the microbubbles are more robust, allowing for a higher mi setting to be used during scanning. the higher mi setting enhances higher intensity bubble signal with improved spatial and temporal resolution which improves image quality and diagnostic accuracy. this study is not looking for diagnosis in patients, which will be done according to standard of care. it is to evaluate whether it is possible to assess myocardial perfusion using the contrast agent sonazoid.

Eligibility criteria:
inclusion criteria: * positive and normal clinical se * able to provide informed consent exclusion criteria: * unable / unwilling to give informed consent * allergy to perfluorobutane * egg allergy * patients with right to left arteriovenous cardiac or pulmonary shunt * unstable heart disease * serious pulmonary disease * pregnancy or lactation women of child bearing potential (defined as not chemically or surgically sterilised or post menopausal)
pnf in subacromial impingement syndrome

Conditions: Subacromial Impingement Syndrome

Summary: although proprioceptive neuromuscular facilitation (pnf) techniques have been used in the treatment of different shoulder problems, pnf techniques in scapular and upper trunk patterns with extremity pattern have not been considered as a possible option for the treatment of subacromial impingement syndrome (sis). the aim of this study was to evaluate the effects of different pnf patterns in sis.

this randomized controlled trial was conducted in the outpatient clinic of a physiotherapy and rehabilitation department in ankara, turkey. the demographic and clinical characteristics of the patients were recorded. voluntary patients with sis were regarded as eligible for the study if they met the inclusion criteria. pain, posture and functionality were assessed before and after intervention. patients who met the inclusion criteria and agreed to participate were randomly allocated to group 1 \[conventional therapy (ct)\], group 2 \[ct+ pnf in extremity pattern\] and group 3 \[ct+ pnf in extremity pattern+pnf in scapula and upper trunk patterns\]. a simple randomization method was used with opaque sealed envelopes containing "a", "b" or "c". group allocation was performed by an independent therapist, not involved in the study. all patients received physiotherapy for approximately 60 mins each session, 3 sessions per week for 6 weeks. conventional therapy consisted of cold pack (15 minutes); pulsed ultrasound therapy (1 watt/cm², 3 mhz, 1:2 pulsed mode; 3 minutes); transcutaneous electrical nerve stimulation (60-120 hz; 20 minutes) and exercises (20 minutes). the exercises included stretching, strengthening and posture exercises. the exercises, and the duration and intensity of conventional physiotherapy were selected according to previous studies which showed that a physiotherapy program 3 times a week for 6 weeks was effective in improving function and relieving pain in sis. the physiotherapy program was applied to all patients at the same intensity by the same physiotherapist and patients did the exercises every day throughout the 6-week period. the patients were also advised to avoid overhead activities.

Eligibility criteria:
inclusion criteria: * patients diagnosed with sis, * aged between 18 and 65 years, * shoulder pain ongoing for more than four weeks, * loss of active shoulder motion or painful rom, * no treatment related to the shoulder in the last 6 months. exclusion criteria: * history of frozen shoulder, * disorders of the acromioclavicular joint, * possession of a curved or hooked acromion, * shoulder instability, * degenerative arthritis of the glenohumeral joint, * calcifying tendonitis, * post-traumatic disorders, * shoulder surgery and/or elbow, hand, wrist and cervical spine disorders, * diseases that can cause positional vertigo.

Keywords: subacromial impingement posture pain proprioceptive neuromuscular facilitation
a single-group clinical trial investigating the effects of a hair vitamin combination on hair growth and hair health

Conditions: Hair Health; Hair Loss

Summary: this clinical trial aims to investigate the effectiveness of two vitamins revive hair supplements in promoting hair growth, reducing hair loss, and improving overall hair health. the products under assessment are hair nutra growth and hair nutra boost. the trial will assess the efficacy of the products to induce better hair growth, reduction in hair loss and shedding, increased hair thickness and fullness, and improvement in hair appearance and vitality over a 12-week testing period. participants will complete study-specific questionnaires at baseline, week 4, week 8, and week 12. participants will also provide photos of their hair at baseline, week 4, week 8, and week 12.


Eligibility criteria:
inclusion criteria: * women aged 30+ self-reported issues with hair growth, shedding, and thinning generally healthy - don't live with any uncontrolled chronic disease must be willing to stop taking any other hair growth supplements or biotin supplements for the duration of the trial in the last three months, has not introduced any new supplements or medications to target hair growth, hair loss, or hair health individuals must agree to refrain from dyeing their hair in the target interest areas until the study is complete willing and able to take high-quality photographs of their hairline exclusion criteria: * any pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders anyone with known severe allergic reactions anyone with a known allergy to any of the ingredients anyone currently using a hair growth supplement anyone currently using biotin anyone with scalp or hair diseases including but not limited to alopecia areata (a hair loss disorder leading to patchy bald spots on the head) women who are pregnant, breastfeeding, or attempting to become pregnant unwilling to follow the study protocol
a trial of [s,s]-reboxetine in patients with chronic painful diabetic peripheral neuropathy.

Conditions: Diabetic Neuropathies

Summary: this is a trial to investigate the effectiveness and safety of \[s,s\]-reboxetine in relieving chronic peripheral pain suffered by patients with diabetes. some evidence for the effectiveness of \[s,s\]- reboxetine in relieving chronic pain has been seen in 3 completed trials.


Eligibility criteria:
inclusion criteria: * male or female of any race at least 18 years of age * diagnosis of painful, distal, symmetrical, sensory-motor polyneuropathy, which is due to diabetes, for at least 1 year * patients at visit 1 must have a score ≥40 mm on the pain visual analogue scale exclusion criteria: * patients with significant hepatic impairment * neurological disorders unrelated to diabetic neuropathy that may confuse the assessment of neuropathic pain * any pain or other condition that may confound assessment or self-evaluation of the pain due to diabetic neuropathy * amputations other than toes * a current or recent diagnosis (past 6 months) or episode of major depressive disorder and/or uncontrolled depression * history of transient ischemic attack or stroke * myocardial infarction or unstable angina within the past three months